DC-SIGN (CD209) Promoter −336 A/G (rs4804803) Polymorphism Associated with Susceptibility of Kawasaki Disease
Kawasaki disease (KD) is characterized by systemic vasculitis of unknown etiology. High-dose intravenous immunoglobulin (IVIG) is the most effective therapy for KD to reduce the prevalence of coronary artery lesion (CAL) formation. Recently, the α2, 6 sialylated IgG was reported to interact with a l...
Saved in:
| Main Authors: | Hong-Ren Yu, Wei-Pin Chang, Lin Wang, Ying-Jui Lin, Chi-Di Liang, Kuender D. Yang, Chiu-Ming Kuo, Yi-Chuan Huang, Wei-Chiao Chang, Ho-Chang Kuo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/634835 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population-Based Study of the Association between Urbanization and Kawasaki Disease in Taiwan
by: Wei-Pin Chang, et al.
Published: (2013-01-01) -
Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
by: Chih-Jen Chen, et al.
Published: (2012-01-01) -
Clinical Manifestations Vary with Different Age Spectrums in Infants with Kawasaki Disease
by: Hao-Chuan Liu, et al.
Published: (2012-01-01) -
DC-SIGN (CD209)-mediated interactions between bacteria, lung cancer tissues, and macrophages promote cancer metastasis
by: Qiao Li, et al.
Published: (2025-06-01) -
FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
by: Ho-Chang Kuo, et al.
Published: (2015-01-01)